Safety, Tolerability, and Pharmacokinetics of Single-Dose DMI019 Nasal Spray in Healthy Participants

Phase 1, randomised, double-blind trial of DMI019 in allergic rhinitis (AR) (8 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Number of Participants With Clinically Significant Changes in Vital Signs at 48 hours, Incidence and Severity of Adverse Events at Day 7 and 4 more. Planned start Sep 2026; status: not yet recruiting.